AngioDynamics (NASDAQ: ANGO), a leading provider of innovative,
minimally invasive medical devices for vascular access, surgery,
peripheral vascular disease and oncology, announced presentations on
NanoKnife® System clinical experience were given at the
Society of Surgical Oncology (SSO) 2012 conference that took place March
21-24, 2012, in Orlando, Fla.
An oral presentation titled, "Image Guided Irreversible Electroporation
in Locally Advanced Pancreatic Cancer: Improved Overall Survival," was
presented by Dr. Robert Martin, University Of Louisville, Department of
Surgery, Division of Surgical Oncology, Louisville, Ky. Additional
authors included Doctors David Hays and Whitney Goodwin, Baptist Health,
Little Rock, Ark.; and Doctors Kellie McFarlin, Madhu Prasad and Vic
Valanovich, Henry Ford Hospital, Detroit, Mich.
In connection with a registry administered by the University of
Louisville, Department of Surgery, Division of Surgical Oncology, 44
patients underwent procedures with the NanoKnife System for unresectable
pancreatic cancer from December 2009 to October 2010. Overall survival
was evaluated and compared to 85 matched stage three patients treated
with standard therapy defined as chemotherapy and radiation therapy
alone.
The authors noted that ninety percent of the patients treated with the
NanoKnife System had chemotherapy alone, or chemo-radiation therapy, for
a median duration of five months before a procedure with the NanoKnife
System. Seventy-three percent underwent chemotherapy or chemo-radiation
after a procedure with the NanoKnife System. The 90-day mortality in
patients who had procedures with the NanoKnife System was two percent.
Comparing patients with NanoKnife System procedures to those receiving
standard therapy, the authors reported a significant improvement in
local progression-free survival, 14 versus six months. Improvement also
was reported for distant progression-free survival, 15 versus nine
months. Overall survival was 20 months versus 13 months.